甘草酸二铵脂质配位体对非酒精性脂肪性肝病大鼠肝组织AMPK信号通路的影响*

doi:10.3969/j.issn.1672-5069.2017.01.015

摘要/Abstract

摘要： 目的研究甘草酸二铵脂质配位体（DGLL）对非酒精性脂肪性肝病（NAFLD）大鼠的治疗作用,并探讨其可能的作用机制。方法以高脂饲料喂养建立NAFLD大鼠模型,在造模成功后分别给予DGLL或多烯磷脂酰胆碱（PPC）灌胃16周。采用免疫组化法检测肝组织磷酸化的磷酸腺苷激活蛋白激酶α（P-AMPKα）蛋白表达,采用Real-time PCR法检测肝组织过氧化物酶体增殖物激活受体γ（PPAR-γ）、肉毒碱棕榈酰基转移酶-1（CPT-1）、葡萄糖转运蛋白4（GLUT-4）、酰基辅酶A氧化酶（ACO）、肝脏型脂肪酸结合蛋白（L-FABP）、乙酰辅酶A羧化酶（ACC）mRNA。结果 DGLL组血清瘦素为（3.87±0.38）ng/ml,显著低于模型组【（4.68±0.39）ng/ml,P<0.01】或PPC组【（4.55±0.24）ng/ml,P<0.01】;DGLL组脂联素为（12.27±0.64）μg/ml,显著高于模型组【（10.46±0.28）μg/ml,P<0.01】,但与PPC组【（12.13±0.56）μg/ml,P>0.05】比,无统计学差异;DGLL组大鼠肝组织P-AMPKα蛋白阳性表达面积为（8.38±3.27）%,显著高于模型组【（1.81±0.90）%,P<0.01】或PPC组【（5.50±0.73）%,P<0.05】;DGLL组肝组织PPAR-γ、CPT-1、GLUT-4 mRNA水平分别为（1.07±0.14、0.91±0.05、1.61±0.54）,显著高于模型组【分别为（0.26±0.12、0.14±0.01、0.10±0.03,P<0.05】,但ACO mRNA水平（0.23±0.09）与模型组比,无统计学差异【（0.24±0.02）,P>0.05】;PPC组PPAR-γ和CPT-1 mRNA水平分别为（0.65±0.16）和（0.22±0.05）,显著低于DGLL组（P<0.05）,而GLUT-4和ACO mRNA水平（1.32±0.12和0.14±0.05）与DGLL组比,无统计学差异（P>0.05）;DGLL组肝组织ACC mRNA水平为（1.67±0.23）,显著低于模型组【（3.31±0.02）,P<0.05】或PPC组【（2.69±0.14）,P<0.05】;DGLL组L-FABP mRNA水平为（1.06±0.04）,显著低于模型组【（1.26±0.02）,P<0.05】,而与PPC组【（1.06±0.09）,P>0.05】比,无统计学差异。结论 DGLL能降低NAFLD大鼠血脂、血糖、胰岛素、HOMA-IR、瘦素水平,升高脂联素,并增加肝组织P-AMPKα蛋白表达,上调PPAR-γ、CPT-1、GLUT-4 mRNA水平、下调L-FABP和ACC mRNA水平,这些作用可能与其激活AMPK通路和改善NAFLD糖脂代谢紊乱有关。

关键词: 非酒精性脂肪性肝病, 甘草酸二铵脂质配位体, 多烯磷脂酰胆碱胶囊, 磷酸腺苷激活蛋白激酶α, 大鼠

Abstract: Objective To study the therapeutic effect of diammonium glycyrrhizinate lipid ligand （DGLL） on non-alcoholic fatty liver disease（NAFLD） and to explore its possible mechanism. Methods The model of NAFLD was established in rats by feeding high fat diet,and then the DGLL was given with polyene phosphatidylcholine capsules （PPC） as control. Serum liver function index,blood lipids and glucose,insulin,leptin, adiponectin were detected. The expression of P-AMPKα was immunohistochemically assayed,and PPAR-γ,CPT1,GLUT-4,ACO,L-FABP and ACC mRNA were detected by real time PCR. Results The serum levels of leptin in DGLL group were （3.87±0.38） ng/ml,much lower than in the model group [（4.68±0.39） ng/ml,P<0.01] or in PPC group[（4.55±0.24） ng/ml,P<0.01];serum adiponectin levels was（12.27±0.64）μg/ml,much higher than in the model【（10.46±0.28）μg/ml,P<0.01】,while it was not significantly different from in PPC group【（12.13±0.56）μg/ml,P>0.05】;the P-AMPKα expression area in liver tissue was （8.38±3.27）%,much higher than in the model 【（1.81±0.90）%,P<0.01】 or in PPC group【（5.50±0.73）%,P<0.05】;the PPAR-γ,CPT-1,GLUT-4 mRNA in liver tissues were （1.07±0.14,0.91±0.05,1.61±0.54,respectively）,much higher than in the model 【（0.26±0.12, 0.14±0.01, 0.10±0.03,respectivelyt,P<0.05】,while the ACO mRNA was not significantly different from in the model [（0.23±0.09）vs. （0.24±0.02）,P>0.05】;the hepatic PPAR-γ and CPT-1 mRNA in PPC group were （0.65±0.16） and （0.22±0.05）,much lower than in DGLL group（P<0.05）,while the GLUT-4 and ACO mRNA were not significantly different from in the DGLL group（P>0.05）;the hepatic ACC mRNA in DGLL group was （1.67±0.23）,much lower than in the model【（3.31±0.02）,P<0.05】 or in the PPC group【（2.69±0.14）,P<0.05】;the hepatic L-FABP mRNA in DGLL group was（1.06±0.04）,much lower than in the model 【（1.26±0.02）,P<0.05】,but not significantly diferent from in PPC group【（1.06±0.09）,P>0.05】. Conclusion We found DGLL could reduce serum transaminase,blood lipids,blood glucose,insulin,HOMA-IR and leptin,increase hepatic PPAR-γ,CPT-1 and GLUT-4 mRNA and decrease the L-FABP and ACC mRNA levels in rats with NAFLD. DGLL could significantly improve liver function and lipid metabolism in NAFLD,which may be related to the activation of AMPK pathway.

Key words: Nonalcoholic fatty liver diseases, Diammonium glycyrrhizinate lipid ligand, Polyene phosphatidyl choline capsules, AMPK, Rats

崔小萌, 刘欣, 史海涛, 赵刚, 程妍, 杨娟, 方媛. 甘草酸二铵脂质配位体对非酒精性脂肪性肝病大鼠肝组织AMPK信号通路的影响^*[J]. 实用肝脏病杂志, 2017, 20(1): 55-59.

Cui Xiaomeng, Liu Xin, Shi Haitao, et al.. Effects of diammonium glycyrrhizinate lipid ligand on AMPKα signaling pathways in rats with nonalcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 55-59.

参考文献

[1] Donati G,Stagni B,Piscaglia F,et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes:role of insulin resistance. Gut,2004,53（7）:1020-1023.
[2] Diehl AM. Fatty liver,hypertension,and the metabolic syndrome. Gut,2004,53（7）:923-924.
[3] 常珊珊,徐济良. 非酒精性脂肪肝发病相关因子的机制研究新进展.南通大学学报（医学版）,2013,33（1）:56-60.
[4] Forbes S,Taylor-Robinson SD,Patel N,et al. Increased prevalence of non-alcoholic fatty liver disease in european women with a history of gestational diabetes. Diabetologia,2011,54（3）:641-647.
[5] Yatsuji S,Hashimoto E,Kaneda H,et al. Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease:s the international autoimmune hepatitis group scoring system useful. J Gastroenterol, 2005,40（12）:1130-1138.
[6] Marchesini G,Bugianesi E,Forlani G,et al. Nonalcoholic fatty liver,steatohepatitis,and the metabolic syndrome. Hepatology,2003,37 （4）:917-923.
[7] 茹仁萍,吴锡铭. 18α甘草酸及其脂质配位体的生物利用度与抗肝损害作用的比较. 浙江医学,2001,23（8）:18-20.
[8] Xu P,Zhang XG,Li YM,et al. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease （NAFLD） in rats. J Zhejiang Univ Sci B,2006,7（8）:627-633.
[9] Savvidou S,Hytiroglou P,Orfanou-Koumerkeridou H,et al. Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD. J Clin Gastroenterol,2009,43（8）:765-772.
[10] Emoto M,Nishizawa Y,Maekawa K,et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care,1999,22 （5）:818-822.
[11] Hawley SA,Davison M,Woods A,et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem,1996,271（44）:27879-27887.
[12] Kemp BE,Stapleton D,Campbell DJ,et al. AMP-activated protein kinase,super metabolic regulator. Biochem Soc Trans,2003,31（Pt 1）:162-168.
[13] Rutter GA,Da Silva Xavier G,Leclerc I. Roles of 5'-AMP-activated protein kinase（AMPK） in mammalian glucose homoeostasis. Biochem J,2003,375 （Pt 1）:1-16.
[14] MacLean PS,Zheng D,Jones JP,et al. Exercise-induced transcription of the muscle glucose transporter （GLUT 4） gene. Biochem Biophys Res Commun,2002,292 （2）:409-414.
[15] Liu Y,Wan Q,Guan Q,et al. High-fat diet feeding impairs both the expression and activity of AMPKa in rats' skeletal muscle. Biochem Biophys Res Commun,2006,339（2）:701-707.
[16] Rangwala SM,Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci,2004,25（6）:331-336.
[17] Lazar MA. PPAR gamma,10 years later. Biochimie,2005,87 （1）:9-13.
[18] Tamori Y,Masugi J,Nishino N,et al. Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characte
ristics of mature 3T3-L1 adipocytes. Diabetes,2002,51（7）:2045-2055.
[19] 王兆君,叶平,张秀锦.衰老对大鼠肝脏组织酰基辅酶A氧化酶水平的影响. 中国动脉硬化杂志,2005,13（1）:10-12.
[20] 王乐,张霞. 非酒精性脂肪肝分子机制的研究进展. 现代预防医学,2010,37（11）:2027-2030.

甘草酸二铵脂质配位体对非酒精性脂肪性肝病大鼠肝组织AMPK信号通路的影响^*

Effects of diammonium glycyrrhizinate lipid ligand on AMPKα signaling pathways in rats with nonalcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	徐飞, 李伟荣. 黄芪甲苷对CCL₄所致肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 808-811.
[3]	高磊, 曹蕾, 王瑞芳, 冯丹丹, 薛娟. 人脐带间充质干细胞移植对酒精性肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 812-815.
[4]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[5]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[6]	林秋香, 王雪雯, 黄祖雄, 潘晨. 灯盏花素对肝脏缺血再灌注损伤大鼠肝脏和肠黏膜屏障功能的保护作用*[J]. 实用肝脏病杂志, 2019, 22(5): 636-639.
[7]	石小龙, 杜睿, 秦革萍, 薛华燕, 张宏鑫. 七氟醚对脓毒症大鼠肝损伤的保护作用及其作用机制研究*[J]. 实用肝脏病杂志, 2019, 22(5): 640-643.
[8]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[9]	王艳, 苏峰, 李园园, 李舒. 蜂毒溶血肽改善非酒精性脂肪肝大鼠肝组织脂肪沉积作用及其机制研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 474-477.
[10]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[11]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[12]	周丽云, 李校天, 李丽, 杨俊超. 1,25（OH）₂D₃通过调节miR-146a水平抑制大鼠肝纤维化的体内和体外观察[J]. 实用肝脏病杂志, 2019, 22(3): 333-336.
[13]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[14]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[15]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.